Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead Sciences (GILD) shares rose 13.6% since its last earnings report. Q2 2026 saw a narrower adjusted loss of $6.75 per share and revenue growth of 10% to $7.80 billion, driven by HIV portfolio and Trodelvy. GILD raised full-year HIV sales growth guidance to 9-10%.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest upside potential, but the large acquisition-related expenses and declining cell therapy sales introduce risk.
Market read
Gilead's earnings beat and raised HIV guidance provide a fresh catalyst for the stock, with potential short-term upside but offset by acquisition costs and weaker cell therapy performance.
What to watch
Potential headwinds from competition in cell therapy and the sizable $11.2B acquisition charge may affect cash flow sustainability.
Background
Gilead's Q2 2026 earnings were released after a month of price appreciation, highlighting strong HIV product performance and new guidance, while noting acquisition costs and weaker cell therapy outlook.
Ticker impact
Gilead Sciences reported Q2 2026 earnings with a narrower loss, beat revenue estimates, and raised full-year HIV sales guidance.
Potential short-term price appreciation of 5-8% as investors digest the beat and guidance lift.
The earnings release is the primary source of new information, includes material financial metrics and guidance updates that directly affect valuation.
Market effects
Positive for the biotech/pharma sector, especially HIV therapeutics, as Gilead's guidance lift may set a benchmark.
U.S. markets may see modest gains in healthcare stocks following Gilead's beat.
Limited to global investors with exposure to Gilead; no broader macro impact.
Counterpoint
Acquisition-related cash outflows and declining cell therapy sales could pressure the stock despite the earnings beat.
Key entities
- CompanyGilead Sciences
Biopharmaceutical company reporting Q2 earnings.
- Acquired CompanyArcellx
Acquisition contributing to in-process R&D expenses.
- Acquired CompanyTubulis
Acquisition contributing to in-process R&D expenses.
- Acquired CompanyOuro Medicines
Acquisition contributing to in-process R&D expenses.
